Clinical Trial

IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open label, single center, dose escalation, and dose extension IIT study aimed at evaluating the safety, efficacy, and pharmacokinetics of IB-T101 in adult patients with advanced clear renal cell carcinoma
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-05; most recent amendment 2026-04-13.
Trial Details
NCT Number NCT06819293
Lead Sponsor Grit Biotechnology
Conditions Advanced Clear Renal Cell Carcinoma, Adult
Enrollment 12 participants
Start Date 2024-12-06
Primary Completion 2027-12-07 (estimated)
Study Completion 2027-12-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-14